The European Hematology Association 26th congress EHA 2021

The European Hematology Association 26th congress EHA 2021

Programme du congrès

Lieu : Online

Pays : Pays-Bas

Langue : ENG

Date de début :

Date de fin :

Spécialités : Hématologie

EHA continues to dedicate its efforts to guiding hematologists in both clinical and research settings. Although face-to-face interactions are an important aspect of any congress, the current pandemic severely limits the possibilities. A core objective of EHA is to provide a platform for networking and connecting hematologists and EHA2021 will be no different. We will strive to maximize opportunities to promote the social side of our congress for our participants. The EHA2021 Virtual Congress will be a key moment to consolidate the knowledge and experience gained worldwide and bring together hematologists in a virtual environment

Toutes les vidéos du congrès ( 15 vidéos )

Suggérer une vidéo

Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphoma

Brentuximab vedotin with chemotherapy for advanced classical Hodgkin lymphoma
  • Date : 17/06/2021
  • 1    
    0

CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL

CAPTIVATE: First-line ibrutinib plus venetoclax for CLL/SLL
  • Date : 17/06/2021
  • 1    
    0

ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R B-cell

ZUMA-3: KTE-X19, an anti-CD19 chimeric antigen receptor T-cell therapy for R/R B-cell
  • Date : 17/06/2021
  • 1    
    0

CLL14: Venetoclax plus obinutuzumab in untreated CLL

CLL14: Venetoclax plus obinutuzumab in untreated CLL
  • Date : 17/06/2021
  • 0    
    0

Interim analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP-CML

Interim analysis from the OPTIC trial, a dose-ranging study of ponatinib for CP-CML
  • Date : 17/06/2021
  • 0    
    0

A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control

A comparison of clinical outcomes from ZUMA-5 and the international scholar-5 external control
  • Date : 17/06/2021
  • 0    
    0

Carfilzomib-lenalidomide-dexamethasone in the management

Carfilzomib-lenalidomide-dexamethasone in the management
  • Date : 17/06/2021
  • 0    
    0

A phase II study of blinatumomab for the treatment of MRD-positive B-cell acute lymphoblastic

A phase II study of blinatumomab for the treatment of MRD-positive B-cell acute lymphoblastic
  • Date : 17/06/2021
  • 0    
    0

Interim results of a phase II study of blinatumomab plus ponatinib for Philadelphia

Interim results of a phase II study of blinatumomab plus ponatinib for Philadelphia
  • Date : 17/06/2021
  • 0    
    0

Fixed-duration ibrutinib and venetoclax for first-line CLL

Fixed-duration ibrutinib and venetoclax for first-line CLL
  • Date : 17/06/2021
  • 0    
    0

Isatuximab, carfilzomib, lenalidomide and dexamethasone (Isa-KRd) in front-line treatment

Isatuximab, carfilzomib, lenalidomide and dexamethasone (Isa-KRd) in front-line treatment
  • Date : 17/06/2021
  • 0    
    0

Once weekly selinexor, carfilzomib, and dexamethasone (XKD)in carfilzomib non-refractory

Once weekly selinexor, carfilzomib, and dexamethasone (XKD)in carfilzomib non-refractory
  • Date : 17/06/2021
  • 0    
    0

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone

Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone
  • Date : 17/06/2021
  • 0    
    0

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R b-cell non-Hodgkin’s lymphoma

Dose-escalation of mosunetuzumab with polatuzumab vedotin for R/R b-cell non-Hodgkin’s lymphoma
  • Date : 17/06/2021
  • 0    
    0

Latest developments in the use of immunotherapy for relapsed or refractory multiple myeloma

Latest developments in the use of immunotherapy for relapsed or refractory multiple myeloma
  • Date : 17/06/2021
  • 0    
    0

Sélection de congrès

9ème Journée Nationale Maladies Rares Immuno-Hématologiques - MaRIH 2023

9ème Journée Nationale Maladies Rares Immuno-Hématologiques - MaRIH 2023
  • Date : 30/06/2023
  • 3416    
    6

International Society on Thrombosis and Haemostasis congress - ISTH 2023

International Society on Thrombosis and Haemostasis congress - ISTH 2023
  • Date : 24/06/2023
  • 5000    
    0

The European Hematology Association - EHA 2023

The European Hematology Association - EHA 2023
  • Date : 08/06/2023
  • 8154    
    0

MDS - 17th International Congress on Myelodysplastic Syndromes

MDS - 17th International Congress on Myelodysplastic Syndromes
  • Date : 03/05/2023
  • 12684    
    0

43e congrès annuel de la Société Française d’Hématologie - SFH 2023

43e congrès annuel de la Société Française d’Hématologie - SFH 2023
  • Date : 29/03/2023
  • 9400    
    7